Bridgewater Associates LP Raises Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bridgewater Associates LP lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,222 shares of the company’s stock after buying an additional 1,144 shares during the quarter. Bridgewater Associates LP’s holdings in Teva Pharmaceutical Industries were worth $418,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co raised its holdings in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Byrne Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $52,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Finally, GAMMA Investing LLC raised its stake in shares of Teva Pharmaceutical Industries by 105.7% during the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after purchasing an additional 1,741 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.8 %

TEVA stock opened at $16.65 on Tuesday. The company has a 50 day moving average of $17.54 and a two-hundred day moving average of $17.36. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 12-month low of $9.35 and a 12-month high of $19.31. The company has a market cap of $18.86 billion, a price-to-earnings ratio of -19.59, a PEG ratio of 1.30 and a beta of 0.87.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TEVA shares. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.